Press Release
CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies
SHENZHEN, CHINA – China Medical System Holdings Limited (867.HK/8A8.SG) (“CMS”, or the “Group”) is pleased to announce that, the New Drug Application for Silevimig Injection (GR1801, the “Product”), a Class 1 therapeutic biological product has been approved by the National Medical Products Administration of the People’s Republic of China (“NMPA”) and the drug registration certificate was obtained on 22 June 2026. The Product is indicated for passive immunization in adults following rabies virus exposure.
Silevimig Injection is the world’s first fully human bispecific antibody targeting dual epitopes of the rabies virus (“RABV”), which is consistent with the recommendations of the World Health Organization (“WHO”) for a “cocktail” therapeutic paradigm. It demonstrates broad neutralization, which can effectively neutralize different viral strains or genotypes of RABV, providing immediate protection. Moreover, it is the passive immunization product with the smallest dose for rabies, resulting in less injection volume and easier administration, which can effectively reduce patient pain and improve compliance. In addition, the Product can be manufactured at scale with standardized processes and controlled production cost, and also carries no risks of blood-borne infections, low immunogenicity, and minimal interference with vaccine-induced active immunization. The market for rabies passive immunization is substantial, yet existing passive immunization products are constrained by low market penetration and limitations in safety and accessibility. The approval of the Product will provide a new treatment option for patients requiring urgent post-exposure management against rabies in China.
The approval of Silevimig Injection expands the Group’s commercialized innovative drug portfolio to 8 products, with 6 more innovative drugs under marketing review and approximately 20 projects advancing clinical development, further strengthening a tiered innovation pipeline. As of now, CMS’s innovation transformation strategy has fully entered the value-harvesting phase. Leveraging the Group’s existing expert network and market resources, the commercialization rollout of Silevimig Injection is expected to proceed steadily providing sustained momentum to the Group’s performance growth.
About Rabies
Rabies is an acute zoonotic disease caused by RABV, clinically characterized by aerophobia, hydrophobia, pharyngeal muscle spasms, and progressive paralysis[1], with a case-fatality rate approaching 100%. At present, there is no proven treatment for rabies once clinical symptoms appear. Standardized post-exposure management, comprising wound care, vaccination, and passive immunization administered as needed, remains the most effective strategy[2]. As vaccine-induced antibodies require 1-2 weeks after the first dose of vaccine injection to reach protective levels, passive immunization provides immediate coverage[1]. According to the National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition), patients with Category III exposure and those with Category II exposure involving severe immunodeficiency should receive passive immunization at the same time as the first dose of rabies vaccine[3]. In China, more than 40 million people are exposed to rabies annually, of whom approximately 40% fall under Category III exposure[1]. However, due to factors such as limited awareness, high cost, and restricted accessibility, only about 15% of Category III cases receive passive immunization[1]. Currently, the primary approved passive immunization option in China is human rabies immune globulin (“HRIG”). However, HRIG must be sourced from healthy donors, making it difficult and costly to obtain. Furthermore, it carries potential risks of blood-borne infections. This has led to a low penetration rate of passive immunization products in China.
More information about Silevimig Injection
Silevimig Injection is a recombinant, fully human bispecific antibody against rabies virus. It targets the viral envelope glycoprotein (G protein) of RABV and blocks its interaction with host receptors by binding to epitopes I and III. Through this mechanism, Silevimig Injection specifically neutralizes the RABV prior to the establishment of full protection by active rabies vaccination.
In a Phase III clinical trial in adults, the Product met its primary efficacy endpoint, demonstrating non-inferior protective efficacy compared with HRIG, the currently most used passive immunization product in China. The study confirmed that the Product provides immediate protection during the early stages of rabies virus exposure without compromising the active immune response induced by vaccination. In addition, a Phase III clinical trial in children and adolescents aged 2 to <18 years is currently ongoing in China. The Product has been granted a patent in China.
In September 2025, the Group through subsidiaries of the Company entered into an Exclusive Collaboration Agreement (the “Agreement”) with Chongqing Genrix Biopharmaceutical Co., Ltd.. In accordance with the Agreement, the Group has obtained exclusive commercialization rights for the Product in mainland China and exclusive licensing rights for the rest of the Asia-Pacific region, the Middle East and North Africa. The collaboration term extends until ten years after the Product receives the marketing approval in Mainland China (the “Initial Term for the Product”). Unless terminated or dissolved under the terms set forth in the Agreement, the Agreement will automatically renew for successive ten-year periods upon expiration of the Initial Term for the Product.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.
Reference:
1. Chinese Center for Disease Control and Prevention. Technical Guidelines for Human Rabies Prevention and Control (2016). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525420231910.pdf
2. Yin Wenwu, Wang Chuanlin, et al. Expert consensus on rabies exposure prophylaxis[J]. Chinese Journal of Preventive Medicine, 2019,53(7): 668-679. DOI:10.3760/cma.j.issn.0253-9624.2019.07.004
3. Chinese Center for Disease Control and Prevention. The National Regulation for the Rabies Exposure Prophylaxis (2023 Edition). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525421817465.pdf
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Carziqo Brings A-DS Autonomous Delivery to San Francisco During Future Mobility Festival
- The company reports rising delivery demand as it positions autonomous logistics as a response to growing operating costs and the need for more efficient urban services.
SAN FRANCISCO, CA, Oct 03, 2026, ZEX PR WIRE — Carziqo says its A-DS autonomous delivery vehicles have begun operating in San Francisco, extending the company’s delivery business during the Carziqo Future Mobility Festival. The development comes as the company reports continued growth in delivery orders across its supported operations and sees increasing opportunities for autonomous technology in the movement of goods.

The San Francisco operation brings a practical focus to the October celebration: how intelligent mobility can support the everyday needs of businesses and consumers. For Carziqo, autonomous delivery represents an opportunity to connect its vehicle technology with a service whose value depends on consistency, convenience and careful management of operating costs.
The company’s recent announcements have emphasized rising A-DS order volumes and the importance of matching delivery demand with available fleet capacity. Carziqo says its priority is to translate that growth into better vehicle utilization and a more dependable service as the business develops.
The economic backdrop gives that objective particular relevance. According to the U.S. Bureau of Labor Statistics, compensation costs for private industry workers rose 3.3 percent in the year ending June 2026, including a 3.1 percent increase in wages and salaries. Although these figures cover private industry broadly, they provide context for the cost pressures businesses face when planning labor-intensive services.
For delivery operators, handling additional orders involves more than adding vehicles. It requires coordinating routes, staffing, vehicle availability and the time needed to complete each task. Higher demand creates a commercial opportunity, but the ability to serve that demand efficiently determines how much value the additional activity can generate.
Carziqo’s approach centers on reducing the manual driving requirements of supported delivery journeys while maintaining human involvement in fleet supervision, maintenance, customer support and situations requiring direct intervention. The company describes this division of responsibilities as a way to organize delivery work more efficiently as volumes increase.
That distinction is central to the business case for autonomous delivery. Automation can change how resources are allocated, but its usefulness depends on the performance of the wider service. A vehicle must be available when needed, assigned a suitable route and supported throughout its operating cycle.
Carziqo describes the A-DS platform as combining automated driving with route planning, connected vehicle monitoring and centralized operational support. Its fleet systems are designed to bring together information about vehicle condition, delivery progress, charging requirements and maintenance needs, helping teams coordinate the vehicles as a network.
For San Francisco, the significance of the deployment lies in applying that approach to local delivery needs. The commercial opportunity will depend on how effectively available capacity meets demand and how consistently the service performs within its operating scope. Those practical considerations give the expansion a business focus beyond the introduction of another autonomous vehicle model.
Carziqo has previously described a phased approach to A-DS deployment, with attention to route suitability, operational stability and service consistency. Experience gathered from its delivery operations is intended to inform improvements in dispatching, maintenance planning and future deployment decisions.
The Carziqo Future Mobility Festival places these developments within the company’s broader ambition to make intelligent transportation relevant to daily life. Held throughout October, the festival centers on greener mobility, connected services and the practical use of technology to improve how people and goods move through cities.
Autonomous delivery gives that theme an everyday point of connection. Behind each delivery is a person waiting for an item or a business fulfilling a customer’s request. The value of the technology ultimately rests on whether it can help complete those tasks reliably and make the service easier to manage.
The festival also provides an occasion to recognize the community supporting Carziqo’s development. In a separate A-DS announcement, the company introduced an additional Wednesday Performance Reward for eligible A-DS rental users, with amounts, claiming arrangements and eligibility governed by the terms published on its platform.
As the company develops its delivery business, its stated priorities include closer coordination between demand and vehicle deployment, management of operating costs and continued improvement of the service experience.
The San Francisco operation adds a new chapter to that effort during the Future Mobility Festival. With A-DS, Carziqo is positioning autonomous delivery as a practical part of its longer-term mobility ambitions—one whose progress will be measured through the everyday work of moving goods and serving customers.
For company information and official updates, visit www.carziqo.com.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Brian Baldari on the Difference Between a Mentor and a Sponsor, and Why It Decides Promotions
-
ResilExec® Coaching founder Brian Baldari, Pharm.D., MBA, on why senior leaders who have plenty of advice and no advocacy stall at the same level for years.
BRICK, N.J., Oct 03, 2026, ZEX PR WIRE — Most senior professionals have someone they go to for advice. Far fewer have someone who argues for them in a room they are not in. According to Brian Baldari, Pharm.D., MBA, founder of ResilExec® Coaching, that distinction accounts for a large share of stalled advancement among otherwise strong performers.
Baldari spent 24 years inside pharmaceutical, healthcare, and enterprise leadership organizations. He held five successive Director-level roles, moved from Director to Vice President and Senior General Manager in 18 months, and led the commercial launch of 14 brands. He now works with Associate Directors, Directors, Senior Directors, Executive Directors, and Vice Presidents inside pharmaceutical, healthcare, and enterprise IT organizations.
“A mentor talks to you. A sponsor talks about you,” Baldari says. “One of those changes your calendar. The other changes your title.”
Advice Is Not Advocacy
Mentorship is widely available and widely encouraged. Many organizations run formal programs for it. A mentor offers perspective, context, and guidance, and that guidance has real value early in a career when the primary gap is knowledge.
Sponsorship operates differently. A sponsor spends their own credibility on someone else. They put a name forward on a succession slate, defend a candidate during calibration, and accept the consequences if the bet does not pay off. That is a materially different act, and it is not something an organization can mandate.
“Leaders collect mentors because mentors are easy to ask for,” Baldari says. “Nobody feels awkward requesting advice. Asking someone to spend their reputation on you is a different conversation, and most people never have it.”
Where the Gap Shows Up
The gap becomes visible at the point where advancement decisions are made collectively. Calibration sessions and succession discussions involve people across multiple functions, many of whom have no direct experience of a given candidate’s work. In those rooms, a candidate is represented by whoever chooses to speak.
“If nobody in that room can describe what you do at enterprise scale, you are not in the conversation, regardless of your review,” Baldari says. “The decision is not made on the strength of your record. It is made on the strength of the description someone else gives of it.”
Baldari notes that this is where strong performers are most often surprised. Their performance ratings are high, their manager is supportive, and the outcome still does not change, because the people who influenced the decision were never engaged.
Sponsorship as a Variable
Sponsorship is one of five variables in Baldari’s Promotion Math
framework, alongside Performance, Visibility, Narrative, and Timing. In his assessment, strong performers optimize the first variable and leave the remaining four unattended, then attribute the result to politics.
“Performance gets you noticed. Positioning gets you promoted,” Baldari says. “Sponsorship is the variable people find hardest to work on, because it requires asking for something rather than producing something.”
What Changes the Outcome
Baldari advises leaders to identify the specific individuals who will participate in the decisions that affect them, then assess honestly whether those individuals could describe their contribution without prompting. In most cases the answer is no, and that is the actionable finding.
From there the work is practical rather than social. It involves delivering value to those individuals rather than checking in with them, framing results at enterprise level rather than functional level, and showing up in forums where that work is visible to people beyond a direct reporting line.
“You do not recruit a sponsor by asking them to be one,” Baldari says. “You give them something worth putting their name next to, and you make sure they understand what it was.”
About Brian Baldari
Brian Baldari, Pharm.D., MBA, based in Brick, New Jersey, is the founder of ResilExec® Coaching and Resilient Performance Group LLC. He spent 24 years inside pharmaceutical, healthcare, and enterprise leadership organizations, held five successive Director-level roles, and advanced from Director to Vice President and Senior General Manager in 18 months. He led the commercial launch of 14 brands across rare and chronic disease categories, led an organization of more than 250 people, and has mentored more than 50 leaders across three continents. Through ResilExec Coaching, he helps Associate Directors, Directors, Senior Directors, Executive Directors, and Vice Presidents accelerate career growth through personalized executive coaching, leadership development, and strategic career positioning.
Media Contact
Resilient Performance Group LLC
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Timothy Caraboolad Publishes a Buyer’s Checklist for New-Build Condos in South Florida
-
Real estate developer Timothy Caraboolad is releasing a set of questions first-time buyers should ask before putting money down on a new-build apartment in South Florida.
A market full of new buildings, and a lot of first-time buyers
Florida, USA, Oct 03, 2026, ZEX PR WIRE — South Florida has no shortage of new construction. Buildings go up fast, sales offices open before the concrete cures, and renderings promise more than any buyer can verify in a single walkthrough.
Timothy Caraboolad, a real estate developer and designer based in Palm Beach, Florida, has spent years on the other side of that process, building high-end custom homes through his firm Lad Design. He says the buyers who end up happiest are the ones who ask harder questions earlier, not the ones who fall for the best rendering.
“A sales gallery is designed to sell you a feeling,” he says. “Your job as a buyer is to slow that down and ask what you’re actually getting for the price.”
What to check before signing anything
Caraboolad points first-time buyers toward a few areas that matter more than finishes.
Construction quality behind the walls. Countertops and cabinetry are easy to judge. What is inside the walls is not. Caraboolad suggests asking who the general contractor is, how long they have built in the area, and whether the building uses concrete or wood-frame construction, since that affects sound, insurance, and long-term durability in a hurricane-prone region.
HOA fees and what they actually cover. New buildings often advertise low fees at launch that rise once amenities open and reserves get funded. “Ask for the projected budget once the building is fully occupied, not just the introductory number,” Caraboolad says. He recommends buyers ask specifically what percentage of the fee goes into reserves, since that determines whether the building can pay for a roof or a seawall repair without a special assessment.
Storm readiness. In South Florida, this is not optional. Buyers should ask about impact windows, generator backup for elevators and common areas, and flood elevation. Caraboolad says a building’s flood zone designation should be requested in writing, not estimated by a sales agent.
Parking and storage, spelled out. Some buildings sell parking as a deeded asset. Others assign it and can reassign it later. Caraboolad says this distinction matters more than most buyers realize until after closing.
Developer track record. A new building has no resale history to check. Caraboolad suggests buyers look at other projects the same developer has completed, not just renderings of the one being sold, and ask how those buildings have held up.
Timing the purchase
For pre-construction units, Caraboolad says the biggest risk is not price, it is timeline. Delays are common, and buyers should understand what happens to their deposit if the closing date slips.
“Get the outside date for completion in writing,” he says. “And ask what your options are if that date passes.”
He also encourages buyers to walk a finished unit in the same building, or a comparable one from the same developer, before relying on a model unit that may use upgraded finishes not included in the base price.
Why this matters for first-time buyers specifically
Caraboolad says first-time buyers face a particular disadvantage: they often do not know which questions are normal to ask, so they accept vague answers.
“An experienced buyer will push back on a soft answer about HOA reserves or insurance history,” he says. “A first-time buyer might just assume that’s how it works. It isn’t. You’re allowed to ask for documentation before you commit.”
His broader point is that a new building can be a strong investment in South Florida, but only when the buyer treats the sales process the same way a developer would: checking budgets, checking materials, and checking the people building it, before checking the view.
About Timothy Caraboolad
Timothy Caraboolad is an entrepreneur, real estate developer, and designer based in Palm Beach, Florida. He is the founder of Lad Design, a South Florida firm building high-end custom homes, and previously founded Arc Design, a luxury residential development and design firm in the Boston area. He holds a Bachelor’s Degree in International Business from Rollins College.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
-
Press Release1 week ago
Just Keepers Spotlights Keeper iD’s New Range of Junior Goalie Gloves
-
Press Release1 week ago
Results Digital Expands Website Design Offerings for General Contractors in Houston TX
-
Press Release6 days ago
New Experiences in Shanghai for Mid-Autumn Festival and National Day! The 2026 International Audio-Visual Arts Carnival Unveils a “Technology + Culture” Audio-Visual Feast
-
Press Release7 days ago
Piya Saliba Releases Free Community Connection Checklist to Help People Build Stronger Relationships
-
Press Release1 week ago
Whimsical Halloween Wardrobe Ready: Arshiner Kids’ Outfits Light Up the Trick-or-Treat Adventure
-
Press Release1 week ago
Painted Brick Digital Named Among Expertise.com’s Top 8 Legal Marketing Companies in Scottsdale
-
Press Release7 days ago
Gary Bassett Shares Lessons From 45 Years Across Finance and Technology
-
Press Release7 days ago
Nivia Fontanez Highlights the Often-Overlooked Role of Radiology Technologists in Patient Care
